Additive pulmonary toxicity with melphalan and busulfan therapy

Area of Science:

• Oncology
• Pulmonology
• Toxicology

Background:

• Chronic myeloid leukemia (CML) management involves chemotherapy.
• Melphalan and busulfan are alkylating agents used in cancer treatment.
• Pulmonary toxicity is a known risk with some chemotherapy drugs.

Observation:

• A 59-year-old patient with CML received sequential melphalan and busulfan therapy.
• The patient developed severe interstitial lung fibrosis.
• The condition manifested after a short treatment duration.

Findings:

• The case suggests a potential link between melphalan and busulfan and interstitial lung fibrosis.
• The pulmonary toxicity may be additive, meaning the combined effect is greater than the sum of individual effects.
• This adverse event occurred despite short-term administration of the agents.

Implications:

• Clinicians should be aware of the risk of severe pulmonary toxicity with sequential melphalan and busulfan in CML patients.
• Further investigation into the additive pulmonary toxicity of these agents may be warranted.
• Monitoring for respiratory symptoms in patients undergoing similar treatment regimens is crucial.